Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation

Haematologica

Volumn 94, Issue 4, 2009, Pages 542-549

  Kröger, Nicolaus ^a   Brand, Ronald ^b   Van Biezen, Anja ^b   Zander, Axel ^a   Dierlamm, Judith ^a   Niederwieser, Dietger ^c   Devergie, Agnès ^d   Ruutu, Tapani ^e   Cornish, Jackie ^f   Ljungman, Per ^g   Gratwohl, Alois ^h   Cordonnier, Catherine ⁱ   Beelen, Dietrich ^j   Deconinck, Eric ^k   Symeonidis, Argiris ^l   De Witte, Theo D ^m  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITY OF HELSINKI   (Finland)

^f BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j UNIVERSITY HOSPITAL ESSEN   (Germany)

^k UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^l UNIVERSITY OF PATRAS   (Greece)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Acute myelogenous leukemia; Cytogenetic abnormalities; Key words:allogeneic stem cell transplantation; Myelodysplastic syndrome; Therapy related

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAMNESIS; ARTICLE; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREDICTION; PRESCHOOL CHILD; RISK FACTOR; SCHOOL CHILD; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; THERAPY RELATED MYELODYSPLASTIC SYNDROME; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66349097167     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.000927     Document Type: Article

References (25)

1. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syn- dromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992;19:47-84.
2. Milligan DW, Ruiz De Elvira MC, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999;106:1020-6.
3. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromo- some aberrations and prognostic fac- tors in therapy-related myelo- dysplasia and acute nonlymphocytic leukemia. Blood 1990;76: 1083-91.
4. Picozzi VJ Jr, Swanson GF, Morgan R, Hecht F, Greenberg PL. 13-cis retinoic acid treatment for myelo- dysplastic syndromes. J Clin Oncol 1986;4:589-95.
5. Ballen KK, Antin JH. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syn- dromes. Hematol Oncol Clin North Am 1993;7:477-93.
6. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syn- drome. Hematol Oncol Clin North Am 1993;7:81-107.
7. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. Clinical cytogenetic associa- tions in 306 patients with therapy- related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43-52.
8. Linassier C, Barin C, Calais G, Letortorec S, Bremond JL, Delain M, et al. Early secondary acute myeloge- nous leukemia in breast cancer patients after treatment with mitox- antrone, cyclophosphamide, fluo- rouracil and radiation therapy. Ann Oncol 2000;11:1289-94.
9. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Risk of sec- ondary myeloid leukemia and myelodysplastic syndrome follow- ing standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with poten- tially curable malignancies. J Cancer Res Clin Oncol 1998;124: 207-14.
10. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400:233-55.
11. Pedersen-Bjergaard J, Andersen MK, Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoiso- merase II inhibitors. J Clin Oncol 1998;16:1897-8.
12. Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL, et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 1993;11:2370-9.
13. Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, et al. Myelodysplastic Syndromes Sub- committee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syn- drome. Bone Marrow Transplant 2006;37:183-9.
14. Yakoub-Agha I, de La SP, Ribaud P, Sutton L, Wattel E, Kuentz M, et al. Allogeneic bone marrow transplan- tation for therapy-related myelodys- plastic syndrome and acute myeloid leukemia: a long-term study of 70 patients - report of the French socie- ty of bone marrow transplantation. J Clin Oncol 2000;18:963-71.
15. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, et al. Hematopoietic cell transplanta- tion in patients with myelodysplas- tic syndrome or acute myeloid leukemia arising from myelodys- plastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007;110:1379-87.
16. Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM, et al. Therapy-related myelodysplastic syndrome: morphologic subclassifi- cation may not be clinically relevant. Am J Clin Pathol 2007;127:197-205.
17. Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM, et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplan- tation. Biol Blood Marrow Transplant 2007;13:655-64.
18. de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, et al. Haematopoietic stem cell trans- plantation for patients with myelodysplastic syndromes and sec- ondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000;110: 620-30.
19. Ballen KK, Gilliland DG, Guinan EC, Hsieh CC, Parsons SK, Rimm IJ, et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodys- plasia. Bone Marrow Transplant 1997;20:737-43.
20. Goldstone AH, Burnett AK, Avivi I et al. Secondary acute myeloid leukemia has a worse outcome in MRC trials. Blood 2002;100:88a [Abstract 322].
21. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prog- nostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004;18: 120-5.
22. Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004;22:2510-1.
23. Arnold R, de Witte T, van Biezen A, Hermans J, Jacobsen N, Runde V, et al. Unrelated bone marrow trans- plantation in patients with myelodysplastic syndromes and sec- ondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 1998;21: 1213-6.
24. Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B, et al. Unrelated donor marrow transplantation for myelo- dysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002;99: 1943-51.
25. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, et al. Myelodysplastic Syndrome Sub- committee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-iden- tical sibling donors in myelodysplas- tic syndromes. Blood 2006;108:836-46.